Repligen Corporation (RGEN) News

Repligen Corporation (RGEN)

Today's Latest Price: $186.99 USD

5.56 (3.06%)

Updated Nov 27 1:00pm

Add RGEN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter RGEN News Items

RGEN News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest RGEN News From Around the Web

Below are the latest news stories about Repligen Corp that investors may wish to consider to help them evaluate RGEN as an investment opportunity.

Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript

Repligen Corporation (RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda -...

SA Transcripts on Seeking Alpha | July 31, 2020

Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Yahoo | July 31, 2020

Repligen Gaps Up On Earnings

Repligen's bioprocessing products are helping customers fast-track Coronavirus vaccines and therapies.

Yahoo | July 30, 2020

Repligen (RGEN) Q2 Earnings and Revenues Top Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance

* Reports record quarterly revenue of $87.5 million * Overall revenue grew 24% year-over-year, with organic growth of 19% * Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth * Completes acquisition of silicone molding and tubing manufacturer Engineered Molding TechnologyWALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.Tony J. H...

Yahoo | July 30, 2020

Repligen Q2 Earnings Preview

Repligen (NASDAQ:RGEN) is scheduled to announce Q2 earnings results on Thursday, July 30th, before market open.The consensus EPS Estimate is $0.16 (-48.4% Y/Y) and the consensus Revenue Estimate is $78.39M (+10.9% Y/Y).Over the last 2 years, RGEN has beaten EPS estimates 75% of the time and has beaten revenue estimates...

Seeking Alpha | July 29, 2020

Coronavirus Play Repligen Near Buy Zone With Earnings Due

Repligen is building a base and near a possible buy range ahead of its next quarterly earnings report, expected on or around Jul. 30.

Yahoo | July 23, 2020

Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 23, 2020

Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?

Is (RGEN) Outperforming Other Medical Stocks This Year?

Yahoo | July 23, 2020

EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?

EXEL vs. RGEN: Which Stock Is the Better Value Option?

Yahoo | July 22, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.622 seconds.